Stockwinners Market Radar for March 08, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:58 EST Arrowhead CFO Myszkowski sells 40,000 common shares - In a regulatory filing, Arrowhead CFO Kenneth Allen Myszkowski disclosed the sale of 40,000 common shares of the company on March 6 at a price of $35.19 per share.

17:39 EST Aesthetic Medical to request hearing before Nasdaq Hearings Panel - Aesthetic Medical announced that it will request a hearing before the Nasdaq Hearings Panel as the next step in the process in seeking an extension to satisfy the minimum bid price requirement set forth in Nasdaq Listing Rule 5550 for continued listing on Nasdaq. Reference is made to the form 6-K of the company filed with the SEC on September 8, 2023 in relation to the letter the company received from the staff of Nasdaq notifying that, as of September 5, 2023, the company's securities had a closing bid price less than $1.00 per share for more than 30 consecutive trading days, which is not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550 for continued listing on Nasdaq. The company was provided a 180-calendar day grace period to regain compliance pursuant to Nasdaq Listing Rule 5810. On March 6, the company received a notification letter from the staff of Nasdaq stating that, the company has not regained compliance with the minimum bid price rule within the 180-calendar day grace period and is not eligible for a second 180-calendar day grace period. Accordingly, the staff had determined to delist the company's securities from Nasdaq unless the company requests a hearing no later than 4:00 p.m. Eastern Time on March 13, 2024. The company intends to timely submit the request for a hearing. This request will ordinarily stay any further action by the staff and the company's securities are expected to continue to be eligible to trade on Nasdaq at least pending the ultimate conclusion of the hearing process.

17:02 EST Graphite Bio declares special dividend estimated at $1.03 per share - Graphite Bio announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Lenz Therapeutics pursuant to the Agreement and Plan of Merger, dated November 14, 2023. The special dividend, which the company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated after deducting certain cash amounts as set forth in the Merger Agreement. The payment date in respect of such special dividend will be on March 21, 2024. The special dividend will not exceed an amount equal to $60M, subject to the adjustments set forth in the Merger Agreement. Payment of the special dividend is conditioned upon the closing of the Merger, which Graphite's stockholders will consider and vote upon at the special meeting of Graphite's stockholders scheduled for 9:00 a.m. PT on March 14, 2024 with closing expected to occur after market close on March 21, 2024, assuming the transaction is approved by Graphite's stockholders and the satisfaction or waiver of all conditions under the Merger Agreement.

16:22 EST Oric Pharmaceuticals CEO Chacko sells 40,000 common shares - In a regulatory filing, Oric Pharmaceuticals president and CEO Jacob Chacko disclosed the sale of 40,000 common shares of the company on March 6 at a price of $16.2095 per share.

16:08 EST Evergy chairman Ruelle to retire, Campbell to serve as next chairman - Evergy announced that Mark Ruelle will not stand for reelection at Evergy's annual meeting on May 7, 2024 as he retires from Evergy's board of directors and his role as chairman at the end of his term. David Campbell, Evergy's president and chief executive officer, has been nominated by the board of directors to assume the role of chairman of the board following Evergy's annual meeting. Ruelle has served as non-executive chairman of the board since 2018, when predecessor companies Westar Energy, Inc. and Great Plains Energy merged to form Evergy. Prior to the merger, he served as a member of the board of directors, president and chief executive officer of Westar Energy since August 2011. "Mark has provided outstanding leadership as chairman of our board for the past six years since the merger that created Evergy," Campbell said. "His vision and experience had a significant positive impact on the company's success, and he has served as a highly valued partner and mentor. We thank Mark for his more than 30 years of exceptional service and leadership at both Westar and Evergy and congratulate him as he begins his next chapter."

16:06 EST Better Choice Company announces 1-for-44 reverse stock split - Better Choice Company announced that it will proceed with a 1-for-44 reverse stock split of its issued and outstanding shares of common stock, par value $0.001, following authorization by its Board of Directors and majority shareholders to effect a reverse stock split by a ratio of not less than 1-for-25 and not more than 1-for-45, at any time on or before March 31, with the Board having the discretion as to whether or not the Reverse Split is to be effected, and the exact ratio to be set at a whole number within the Reverse Split Range. The Board approved the Reverse Split on March 4. The Reverse Split will be effective on March 20, and will begin trading on a post-split basis at the market open on March 21. In conjunction with the Reverse Split, the CUSIP number will be changed to 08771Y 402.

16:00 EST Amplify Energy trading resumes

14:49 EST Amplify Energy trading halted, news pending

14:01 EST Starwood Capital signs LOI for hotels deal with Jaws Mustang Acquisition - Investment entities affiliated with Starwood Capital Group that own interests in a portfolio of hotels comprised of the 1 Hotels properties in Manhattan and Brooklyn, and the De Vere Portfolio in the United Kingdom, and Jaws Mustang Acquisition Corp (JWSM), a special purpose acquisition company, announced that they have signed a non-binding letter of intent, or LOI, for a potential business combination. Under the terms of the LOI, following the consummation of the Business Combination, the combined public company would be listed on a national securities exchange. Under the terms of the LOI, the combined public company would become the direct or indirect owner of the Starwood Capital Entities' interests in ten properties constituting an initial portfolio. It is estimated that the initial portfolio earned $52M of Net Operating Income, or NOI, at the property level for the year ended December 31, 2023, and the initial portfolio is projected to earn NOI at the property level of $62M for the year ending December 31, 2024. The 1 Hotel Brooklyn Bridge and the 1 Hotel Central Park will continue to be externally managed by SH Group Hotels & Residences U.S., and the De Vere Portfolio will continue to be managed by its internal operational team. It is expected that on an ongoing basis, the combined public company will seek to acquire additional hotel properties, including 1 Hotels properties. The Starwood Capital Entities and Jaws intend to finalize their definitive business combination agreement in the coming weeks and will announce additional details at that time, the parties stated.

13:50 EST Amplify Energy down 34% after report of spill from Beta Offshore platform - Shares of Amplify Energy are down $2.15, or 34%, to $4.11 in Friday afternoon trading following a report that investigators in California filed a hazardous materials spill report detailing an overflow of petroleum coming from an offshore platform belonging to Beta Offshore, a subsidiary of Amplify.

13:46 EST Amplify Energy trading resumes

13:41 EST Turkcell trading halted, news pending

13:02 EST Baker Hughes reports U.S. rig count down 7 to 622 rigs - Baker Hughes reports the U.S. rig count is down 7 from last week to 622 with oil rigs down 2 to 504, gas rigs down 4 to 115 and miscellaneous rigs down 1 to 3. The U.S. rig count is down 124 rigs from last year's count of 746 with oil rigs down 86, gas rigs down 38 and miscellaneous unchanged. The U.S. offshore rig count is unchanged at 21, up 7 year-over-year.

12:29 EST Rivian CEO says over 68,000 R2 reservations taken in under 24 hours - RJ Scaringe, founder and CEO of Rivian Automotive, tweeted: "Overwhelmed by the wonderful response to our new vehicles: R2, R3 and R3X. In less than 24 hours, we've taken more than 68,000 R2 reservations. We are thrilled to see this vehicle resonate so strongly with our community!" Reference Link

12:00 EST a.k.a. Brands falls -16.2% - a.k.a. Brands is down -16.2%, or -$1.93 to $10.00.

12:00 EST OppFi falls -20.6% - OppFi is down -20.6%, or -78c to $3.01.

12:00 EST HCI Group rises 16.0% - HCI Group is up 16.0%, or $15.86 to $115.07.

11:50 EST SWVL Holdings Corp trading resumes

11:33 EST Lytus Technologies Holdings Ptv Ltd trading resumes

11:28 EST Lytus Technologies Holdings Ptv Ltd trading halted, volatility trading pause

10:42 EST BlackRock to acquire SpiderRock Advisors, terms not disclosed - BlackRock has agreed to acquire the remaining equity interest in SpiderRock Advisors, a provider of customized option overlay strategies in the U.S. wealth market. This transaction expands on BlackRock's minority investment in SRA made in 2021 and reinforces BlackRock's commitment to personalized separately managed accounts, or SMAs, the company stated. "By giving BlackRock more SMA capabilities, this acquisition will enable us to meet growing demand from wealth managers for personalized, tax-efficient portfolios. We look forward to fully integrating SRA's team and capabilities into our U.S. Wealth Advisory business and to further expanding our offerings in SMA solutions," said Joe DeVico, Co-Head of BlackRock's U.S. Wealth Advisory business. The transaction, expected to close in Q2, is subject to customary closing conditions. The financial impact of the transaction is not material to BlackRock earnings. Financial terms were not disclosed.

10:34 EST Bitcoin raises above $70,000 for first time - Publicly traded companies in the crypto space include Bit Digital (BTBT), Coinbase (COIN), Core Scientific (CORZ), Greenidge Generation (GREE), Marathon Digital (MARA), MicroStrategy (MSTR), Riot Platforms (RIOT), Stronghold Digital Mining (SDIG) and TeraWulf (WULF).

10:07 EST Kymera Therapeutics presents preclinical data for STAT6, TYK2 degrader programs - Kymera Therapeutics announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 and TYK2 are being presented in the poster session at the American Academy of Dermatology's Annual Meeting in San Diego, California. Kymera's oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today's poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting. Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025. The findings presented today demonstrate that in preclinical studies, KT-621, Kymera's first-in-class oral STAT6 degrader, was exquisitely selective for STAT6 over other STATs and fully blocked IL-4/IL-13 functions in key human TH2 cellular assays with picomolar potency that was superior to dupilumab. At low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated. In a MC903-induced atopic dermatitis mouse model, KT-621 demonstrated robust degradation of STAT6 in spleen and marked reduction of total serum IgE comparable to the activity of dupilumab. These data demonstrate the potential of KT-621 for the treatment of atopic dermatitis and other allergic diseases with best-in-pathway potential given its dupilumab-like activity profile and the convivence of an oral pill. Additionally, in preclinical studies, KT-294, Kymera's first-in-class highly selective oral TYK2 degrader, demonstrated picomolar degradation potency and potent inhibition of the IL-23, IL-12 and Type I IFN pathways, showing its potential to recapitulate the biology of human TYK2 loss-of-function profile. KT-294, does not impact any of the other Janus kinase proteins and in doing so spares IL-10, unlike the TYK2 small molecule inhibitor, deucravacitinib, which is important in inflammatory bowel disease. In addition, TYK2 degradation leads to superior inhibition of the Type 1 IFN pathway compared to TAK-2791, which is relevant to the treatment of interferonopathies. The biological differentiation of the TYK2 degrader, KT-294, combined with the ability to provide deep and sustained TYK2 knockdown in vivo with low daily oral doses, has the potential to deliver a best-in-class TYK2 profile with broad activity across multiple IL-12/IL-23- and IFN-driven immune-inflammatory diseases potentially reaching pathway biologics activity. The company plans to share additional preclinical data for KT-621 and KT-294 at upcoming medical meetings in 2024.

10:05 EST Ascent Solar provides corporate update on customer pipeline, revenue potential - Ascent Solar Technologies published a corporate update detailing its customer and revenue potential, as well as its strategy to meet growth opportunities in its two primary customer verticals of aerospace and agrivoltatics. The published report can be found here. The report outlines revenue projects for the remainder of 2024, including $1M to $1.2M in Q2; $3M to $5M in Q3; and $5M to $7M in Q4, totaling $9M to $13.2M for the entire year. Further, the Company anticipates 2025 revenue reaching $50M to $80M. These figures are estimated based on current customer discussions and testing coupled with a rapidly growing market opportunity in aerospace and photovoltaics, and does not reflect revenue under contract. The report also outlines the competitive advantages possessed by Ascent, outlines the Company's robust patent portfolio, and details its customer-acquisition strategies within its respective market focuses of aerospace and agrivoltaics it is already commercially active in. This report follows Ascent's February 2024 announcement about its solar module products being selected to fly on NASA's upcoming Lightweight Integrated Solar Array and AnTenna mission, scheduled for launch this summer.

10:00 EST Delek Logistics falls -11.0% - Delek Logistics is down -11.0%, or -$4.89 to $39.66.

10:00 EST Nuscale Power rises 11.0% - Nuscale Power is up 11.0%, or 49c to $4.95.

10:00 EST Samsara rises 13.4% - Samsara is up 13.4%, or $4.59 to $38.95.

09:47 EST Gates Industrial rises 8.9% - Gates Industrial is up 8.9%, or $1.38 to $16.84.

09:47 EST Samsara rises 11.8% - Samsara is up 11.8%, or $4.06 to $38.42.

09:47 EST Delek Logistics falls -12.4% - Delek Logistics is down -12.4%, or -$5.51 to $39.04.

09:44 EST DHC Acquisition Corp trading halted, volatility trading pause

09:39 EST Amylyx drops 85% after ALS trial did not meet primary endpoint - Shares of Amylyx Pharmaceuticals are down $16.22, or 85%, to $2.75 after the company announced that PHOENIX, a placebo-controlled Phase 3 clinical trial of AMX0035 in people living with amyotrophic lateral sclerosis, or ALS, did not meet its primary endpoint.

09:38 EST Aptorum Group Ltd trading resumes

09:33 EST Aptorum Group Ltd trading halted, volatility trading pause

09:29 EST Amylyx reports PHOENIX ALS trial did not meet primary endpoint - Amylyx Pharmaceuticals announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035, also known as ursodoxicoltaurine, RELYVRIO in the U.S., ALBRIOZA in Canada, in people living with amyotrophic lateral sclerosis, or ALS. PHOENIX did not meet its primary endpoint of reaching statistical significance as measured by change from baseline in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale total score at Week 48, nor was there statistical significance seen in secondary endpoints. Amylyx plans to present the data from PHOENIX at an upcoming medical meeting and will publish the results in a medical journal later this year. "Amylyx will continue to engage with regulatory authorities and the broader ALS community to discuss the results from PHOENIX within the next eight weeks and make informed decisions. Amylyx intends to share plans for RELYVRIO/ALBRIOZA in ALS, which may include voluntarily withdrawing RELYVRIO/ALBRIOZA from the market. At this time, RELYVRIO/ALBRIOZA and its related patient support program will continue to be available for people living with ALS. Amylyx has voluntarily decided to pause promotion of the medication during this time," the company stated. "The global, randomized, double-blind, placebo-controlled Phase 3 ORION clinical study of AMX0035 in PSP remains ongoing. The first participant was dosed in December 2023, and the Company is planning for an interim analysis. Topline results continue to be anticipated in 2025 or 2026. Data from the ongoing 12-participant, single site, open-label Phase 2 HELIOS clinical study are demonstrating evidence of clinical activity of AMX0035 in Wolfram syndrome. This study is fully recruited, and the Company plans to present preliminary data in the second quarter of 2024," the company added.

09:21 EST NRSInsights says February same-store sales increased 3.5% - Same-store sales increased 3.5% from a year earlier. In January 2024, average sales had increased 1.4% compared to January 2023. NRS retail stores in Arizona, Montana and Wyoming generated the highest rates of year-over-year increases. Same-store sales increased 7.4% compared to January 2024, consistent with the expected seasonal rebound from the post-holiday dip in January. Same-store sales in January 2024 had decreased 10.0% compared to December 2023. For the three months ended February 29, 2024, same-store sales increased 2.8% compared to the three months ended February 28, 2023. The number of items sold increased 4.4% compared to February 2023, the same rate of increase as for January 2024 compared to January 2023. The average number of transactions per store increased 2.0% compared to February 2023. For January 2024, the average number of transactions had decreased 0.6% compared to January 2023. A dollar-weighted average of prices for the top 500 items purchased increased 1.2% year-over-year, an increase from the 0.3% year-over-year increase recorded in January 2024, but still well below the 2023 peak level of 5.3% in September.

09:10 EST California Resources assessing ruling, expects to continue to execute plans - In a regulatory filing, California Resources Corporation provided the following update regarding the previously disclosed Kern County Environmental Impact Report litigation: "On March 7, 2024, a California appellate court delivered an opinion finding certain deficiencies in the Kern County EIR and enjoining reliance on the Kern County EIR in connection with the issuance of oil and natural gas permit approvals until such deficiencies are remedied. As we assess next steps and potential timelines, we expect to continue to execute the capital and drilling programs described in our fourth quarter 2023 earnings release and our recently filed Annual Report on Form 10-K. As previously disclosed, if we are not able to obtain new well permits in 2024, we plan to run a one rig program with a $200M to $240M total capital program in 2024 and would expect a 5% to 7% entry to exit production decline rate, without taking into account our pending Aera merger." Reference Link

09:05 EST Safe and Green Development secures financing for Norman Berry expansion - Safe and Green Development Corporation announces an update on the Norman Berry Village property in Atlanta, GA. David Villarreal, President & CEO of SG DevCo, stated, "It is with great pleasure for me to announce the progression of the Norman Berry project. We have secured financing to acquire the previously announced ROW on the property and an 18,000 square foot adjacent parcel that we believe will collectively significantly increase the value of the Norman Berry parcel." There are planned additional phases of construction for the Norman Berry Village project's design, and the completed project is expected to feature two buildings housing 134 units, offering a blend of one and two-bedroom apartments.

09:01 EST SOS Limited provides update on Super-Computing Centers in the U.S. - SOS Limited provides update of its two Super-Computing centers in the U.S. SOS Ltd is providing an interim operating snapshot of it's North American Super-Computing Centers. Between January 2023 and February 29, 2024 SOS has mined a total of 29.434 BTC. Through its majority owned joint venture, FD LLC, SOS operates 726 Thor miner S99 in the Wisconsin Super-Computing Center and 1,086 Thor miner S99 in the Texas Super-Computer Center. Assuming a per unit price of 61,000 USD, the total BTC output value for these centers was approximately $1.8M. Additionally, FD Ltd., is hosting approximately 7400 S19 XP miners in the Texas site which has a 42MW capability. Since March 2023, the company has generated approximately $5M in hosting revenues.

08:52 EST Acumen presents sabirnetug fluid biomarker, target engagement analyses - Acumen Pharmaceuticals presented cerebrospinal fluid biomarker data from the sabirnetug Phase 1 INTERCEPT-AD trial in an oral presentation at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal, and online. Acumen also presented a poster showcasing the method used to develop a first-of-its-kind assay to measure target engagement of an AbetaO-selective antibody. Acumen's sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AbetaOs, a soluble and highly toxic form of Abeta that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration. Positive topline results from 62 participants dosed in the Phase 1 INTERCEPT-AD trial were reported in July 2023, and additional insights from exploratory analyses have further confirmed sabirnetug's proof-of-mechanism and broad therapeutic potential as a next-generation treatment for early AD. Sabirnetug Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study in Early AD: Several key CSF biomarkers are associated with the pathological changes that occur in AD, and evidence suggests these biomarkers may better reflect the underlying pathology of AD than imaging alone. Results from CSF samples collected before and after drug exposure in the INTERCEPT-AD study were presented and assessed for biomarkers indicative of amyloid pathology, tau pathology, neuronal injury and synaptic injury. Sabirnetug had an observed dose-dependent trend in the multiple ascending dose cohorts on CSF levels of pTau181, pTau217 total tau, neurogranin and the Abeta42/Abeta40 ratio, consistent with the downstream pharmacologic effects after just three administrations of the drug. Key findings include: Improvements in biomarkers associated with AD pathology, including significantly lowered CSF levels of neurogranin and pTau181 and trending toward an increasing Abeta42/40 ratio using 60 mg/kg Q4W as compared to the placebo group; A nominally significant correlation between target engagement of AbetaOs and change in neurogranin across all doses, supportive of drug effect; and A trend in correlation between target engagement of AbetaOs and change in p-tau181 across all doses, also supportive of drug effect. These findings support a biological link between sabirnetug and neurogranin and pTau181 and are consistent with sabirnetug's proposed mechanism of action and intended target engagement of AbetaOs, as sabirnetug's effects on these two biomarkers are more closely related to binding of AbetaOs than plaque reduction. Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug-Amyloid Beta Oligomer Complexes in Human CSF Additionally, Acumen presented a poster detailing its method to develop the first assay to directly measure target engagement of AbetaOs by an immunotherapy in the INTERCEPT-AD trial. The novel assay configuration was tailored to selectively detect sabirnetug-AbetaO complex in CSF as a direct measure of target engagement, showing clear dose-related increases in target engagement across all cohorts. This data also informed development of a pharmacokinetic-pharmacodynamic model, which ultimately demonstrated that the highest doses used in INTERCEPT-AD approached maximal target engagement, as was presented in October 2023. Acumen is on track to initiate a Phase 2 trial evaluating sabirnetug in the first half of 2024 and a Phase 1 subcutaneous study in mid-2024.

08:36 EST Neptune Wellness appoints Michael De Geus as interim president, CEO - Neptune Wellness Solutions announced the Company's Board of Directors has named Board member Michael De Geus Interim President and CEO, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and CEO since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Interim COO of Neptune. He will continue his role at Biodroga concurrently with his interim appointment.

08:33 EST Lifeward highlights two research publications on ReStore Exo-Suit - ReWalk Robotics highlighted two recent research publications that demonstrate the effectiveness of the unique propulsion training capabilities of the ReStore Exo-Suit for post-stroke rehabilitation. The most recent publication, from the University of Pecs in Hungary, titled "Investigation of the Effectiveness of the Robotic ReStore Soft Exoskeleton in the Development of Early Mobilization, Walking, and Coordination of Stroke Patients: A Randomized Clinical Trial" examined key walking metrics for two groups of post-stroke patients, randomized to either a conventional therapy program or a program which included training with the ReStore Exo-Suit. The ReStore intervention group demonstrated significant improvements compared to the control group, including a 56% increase in 10-meter walking speed, and a 68% improvement in 6-minute walking distance, and the improved performance was demonstrated to persist at the post-intervention follow up assessment. A second study from Boston University was presented in an abstract titled "Durable Improvements in Post-Stroke Walking Speed and Distance Following High-Intensity Training with Soft Robotic Exosuits." This study demonstrated that a 4-week program of intensive gait training with the ReStore Exo-Suit for individuals post-stroke resulted in clinically meaningful increases in walking speed and walking distance which endured a month after the individual had completed the training program. These improvements in speed and distance were accompanied by significant improvements in propulsion mechanics of the paretic limb.

08:32 EST LM Funding announces 1-for-6 reverse stock split - LM Funding America announced a 1-for-6 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on March 12, 2024. Bruce Rodgers, Chairman and CEO of LM Funding, stated, "We believe that our business fundamentals are currently strong and that we continue to make good progress, as evidenced by our 1700% year-over-year revenue growth in the third quarter of 2023. Notably, as previously reported, the stockholders' equity of LM Funding was $35.9 million, or $2.45 per share (or $14.70 per share after giving effect to the reverse split announced today), as of September 30, 2023, and yet our current share price remains below the Nasdaq minimum bid price requirement of $1.00. We believe this share consolidation will not only ensure we meet the continued listing requirements, but also help us to attract a broader universe of investors, including institutional investors and retail brokers that encounter share price restrictions. Importantly, the pro-rata ownership of each shareholder will remain unchanged as a result of the reverse split, and we believe this share consolidation will tighten our public float and enhance our capital structure as we continue to execute on our business model."

08:19 EST GameSquare completes FaZe Clan acquisition - GameSquare Holdings (GAME) and FaZe Holdings (FAZE) announced the completion of GameSquare's merger with FaZe that was originally announced on October 20, 2023. As a result of the merger, and effective as of the close of trading on March 8, 2024, FaZe's common stock and FaZe warrants will cease trading. As a combined company, GameSquare has become one of the largest gaming and esports organizations in the world based on the Company's audience reach of one billion. In addition, the Company is focused on revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences through a purpose-built next generation media platform that includes award winning marketing and creative services, data and analytics solutions, and Faze Clan, one of the most prominent and influential gaming organizations in the world. Throughout 2023, FaZe has been focused on reducing costs and driving efficiencies. As a result, FaZe removed approximately $31 million of annualized operating costs in the 2023 third quarter compared to the 2022 fourth quarter. FaZe expects to remove approximately $15 million of additional annualized costs during 2024.

08:12 EST Onconova announces rigosertib poster selected for AACR 2024 - Onconova Therapeutics announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024 in San Diego, CA. Poster Title: Rigosertib promotes anti-tumor activity of cancer cells via CETSA revealed novel targets and activates NLRP3-dependent inflammatory responses. Brief Overview: Onconova and its collaborators conducted a series of biochemistry and molecular and cell biology assays to study rigosertib's molecular and inflammation-based targets. The team used a specialized mass spectrometry assay as one of the tools to identify new targets which were then validated as novel targets of rigosertib. Conclusions: This work identified a series of cellular and inflammatory targets that may be affected by rigosertib. In particular, the research highlighted target activity through RAS-MAPK signaling, ROS-mediation JNK activation, and tumor microenvironment reprogramming through NLRP3 activation, which may contribute to preclinical and clinical synergistic effects with checkpoint inhibitors. The identification of these targets and signaling pathways may be helpful in the design of clinical trials to address difficult-to-treat cancers.

08:09 EST Applied Digital provides update on anchor tenant at Ellendale HPC facility - Applied Digital Corporation announced it has extended the original 45-day negotiation period announced in January on the conditional agreement with an anchor tenant to provide datacenter capacity at its Ellendale, North Dakota campus until March 30, 2024. The conditional agreement is for a total of 100MWs for a term of 10 years.

08:09 EST Daxor announces new data on benefits of BVA - Daxor Corporation announces new data from Duke University Medical Center validating the benefits of blood volume analysis, BVA, in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference, THT, which brought together the world's leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024. Veraprapas Kittipibul M.D., lead investigator of the study concluded that: Heterogeneity in volume exists across renal function which can only be accurately measured with BVA. Patients with large volume expansion had worsening renal function, showing the urgent need for care. Pressure-volume correlation is consistently weak across renal function, showing that BVA is the right tool. Anemia, especially dilutional anemia, is more prevalent in worse renal function, also detectable by BVA. "The cornerstone of heart failure care is volume management, and an accurate diagnosis of this is crucial, especially in patients at significant risk for kidney disease," said Michael Feldschuh, CEO and President of Daxor. "Our BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost of care."

08:08 EST Treasure Global's ZCITY store surpasses expectations, achieves milestones - Treasure Global announced the success of ZCITY's Premium Store, achieving significant milestones in the first four months following its launch. The Premium Store has not only surpassed sales expectations but has also significantly enhanced user engagement. The Company believes that the success of its ZCITY Premium Store may contribute to increased revenue growth for the Company. Sam Teo, Chief Executive Officer of Treasure Global, expressed his enthusiasm for the performance of the ZCITY Premium Store: "We are thrilled with the significant sales and revenue growth achieved by the Premium Store. The success of the Premium Store reflects our unwavering commitment to innovation and delivering exceptional value to our users."

07:45 EST Baidu launches China's first 24/7 robotaxi service - Baidu announced a significant operation upgrade for Apollo Go, its autonomous ride-hailing service platform. Apollo Go is now offering 24/7 autonomous driving service in selected areas of Wuhan, becoming China's first provider to offer such service. This expansion to round-the-clock operations represents a significant milestone for Apollo Go, providing non-stop autonomous driving services for a wider range of needs and potential users. The extended service hours accommodate users with nighttime travel needs, ensuring a safer and more convenient service.

07:31 EST Eli Lilly falls $3.16 to $777 after FDA delays decision on Alzheimer's drug

07:13 EST SciSparc announces enrollment of first patient in trial for children with ASD - SciSparc announced that the first patient has been enrolled in the Company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment of children with autism spectrum disorder between the ages of 5 and 18. Autism, also referred to as autism spectrum disorder, is one of the most common developmental disabilities globally with a prevalence of approximately one in 36 children, according to estimates from the Centers for Disease Control and Prevention's Autism and Developmental Disabilities Monitoring Network and is accompanied by an unmet need for efficient and safe treatments. The Company's goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.

07:06 EST Lifeist Wellness amends consulting agreement with Singular Narrative Management - The Company has amended its Consulting Agreement with Singular Narrative Management for the continued provision of strategic business consulting, product development, and brand marketing services to the Company as well as other services that do not include investor relations or promotional activities, originally announced on June 30, 2023. The amended Agreement is effective as of February 1, 2024, and only changes the compensation payable to Singular which remains payable in securities of the Company reflecting Singular's substantial time commitment and dedication in providing the Services. Pursuant to the Agreement, Lifeist shall pay a monthly fee of $40,000 to Singular for the provisions of the Services, after such services have been provided in the particular month, to be satisfied in common shares of the Company and common share purchase warrants, with the number of Shares issuable to Singular determined by dividing $30,000 by the 5-day volume-weighted average price for the last five days of the month in which the services are provided and Warrants issuable to Singular determined by dividing $10,000 by such VWAP. The exercise price of the Warrants shall equal the greater of the "Market Price" on the trading day prior to the date of issuance of the Warrants and $0.05 and the Warrants expire 5 years from the date of issuance. The term of the amended Agreement is for an additional of 6 months and may be terminated by either party with 30-days' prior notice and is automatically renewable thereafter for additional one-month periods unless otherwise terminated by either party.

07:04 EST Lifeist Wellness' Aussie Vapes granted import license in Australia - Lifeist Wellness announcd that its wholly-owned subsidiary, Australian Vaporizers, is among the first companies in Australia to be granted a Therapeutic Goods Administration import license for aromatherapy vaporizer devices. The TGA recently introduced regulations to address concerns related to the misuse of nicotine vaping devices by minors, and as of March 1, 2024, began requiring a special import license for entities seeking to import such devices for sale. Aussie Vapes was granted one of the first such licenses before the deadline. As an established market leader in Australia, Aussie Vapes recognizes that navigating the aromatherapy vaporizer import license application process presents a complicated challenge for smaller participants in the space. TGA regulations demand meticulous attention to detail, comprehensive and current documentation, and a clear understanding of rapidly evolving new industry requirements. The regulatory framework is necessarily strict and the application process can be time consuming, requiring a substantial investment of time and resources. In light of those facts and with an eye toward the future, Aussie Vapes is pleased to report the formation of its new B2B subsidiary, Wholesale Vaporizers. As the new market landscape for these devices continues to evolve in Australia, Aussie Vapes will take a leading role in exploring ways to use our import license to help support smaller retailers in a fully regulatorily compliant and transparent fashion. Aussie Vapes fully supports the TGA in their efforts to restrict and reduce the abuse of nicotine products by minors and looks forward to opportunities for comment and contribution to future policy making to further refine the mechanisms by which to best achieve those goals. We are actively engaged with industry associations as part of a strategic initiative to foster stronger relationships with regulators and actively contribute to the continued formulation of effective regulations in the future. By participating in industry associations, Aussie Vapes can be at the forefront of discussions, offering insights and expertise that contribute to the development of balanced and informed regulatory frameworks.

07:02 EST OTC Markets welcomes Remark Holdings to OTCQX - OTC Markets Group announced Remark Holdings has qualified to trade on the OTCQX Best Market. Remark Holdings Inc. previously traded on NASDAQ.

06:58 EST Clarus board approves increased ownership of two large shareholders - The board of directors for Clarus has approved the respective requests of two of its largest shareholders, Greenhouse Funds LLLP and Clarus Executive Chairman Warren Kanders and its affiliates, to be permitted under the company's Rights Agreement dated as of February 12, 2008, to increase their beneficial ownership. Greenhouse and Kanders have been permitted to increase their positions to up to 15.0% and 26.7% of the company's outstanding shares of common stock, respectively. Greenhouse has beneficial ownership of 4,538,107 shares of the Company's common stock, as publicly disclosed by Greenhouse in the Schedule 13G as of December 31, 2023, filed by it with the Securities and Exchange Commission on February 14, 2024, which represents approximately 11.9% of the Company's outstanding shares of common stock. Kanders has beneficial ownership of 6,525,421 shares of the Company's common stock, as publicly disclosed by Kanders in the Schedule 13D/A filed with the Securities and Exchange Commission on January 30, 2024, which represents approximately 16.7% of the Company's outstanding shares of common stock. The Company's determination to authorize Greenhouse's and Kanders' requests to raise their respective stakes is conditioned upon, and subject to, among other things, Greenhouse and Kanders not increasing each of their respective beneficial ownership to more than 15.0% and 26.7%, respectively, of the Company's outstanding shares of common stock, and Greenhouse and Kanders increasing their respective positions to up to 15.0% and 26.7%, respectively, within the next twelve months. In the event that Greenhouse or Kanders subsequently reduces their respective beneficial ownership to below 9.9%, they would need to obtain a new approval from the Company's board of directors before seeking to again increase their respective beneficial ownership to in excess of 9.9% of the Company's outstanding shares of common stock.

06:47 EST Eli Lilly reports FDA to convene PCNS meeting to discuss TRAILBLAZER-ALZ 2 trial - Eli Lilly announced that the FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee, or PCNS, to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease. The FDA has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design of the TRAILBLAZER-ALZ 2 study, including its limited-duration dosing regimen that allowed patients to complete treatment based on an assessment of amyloid plaque and the inclusion of participants based on tau levels. The date of the advisory committee meeting for donanemab has yet to be set by the FDA, and, as a result, the timing of expected FDA action on donanemab will be delayed beyond the first quarter of 2024. While it is unusual for an advisory committee to occur after the anticipated FDA action date, the advisory committee meeting for donanemab follows similar meetings for the two other amyloid plaque-targeting therapies the FDA has approved.

06:03 EST SSR Mining announces executive leadership changes - SSR Mining announces the reorganization of key roles and responsibilities within its executive leadership team. Michael Sparks, currently Executive Vice President, Chief Legal and Administrative Officer, will take on the role of Executive Vice President, CFO. Sparks succeeds Alison White who is leaving the company to pursue other opportunities. F. Edward Farid, currently Executive Vice President, Chief Corporate Development Officer, will take on the role of Executive Vice President, Chief Strategy Officer. Finally, Joanne Thomopoulos, currently Vice President, Human Resources, will become Executive Vice President, Human Resources. The changes to the executive leadership team are effective immediately.

05:04 EST Yatsen to implement ADS ratio change - Yatsen announced that, it will change the ratio of its American depositary shares, or ADSs, to its Class A ordinary shares from one ADS representing four Class A ordinary shares to one ADS representing 20 Class A ordinary shares. For the company's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-five reverse ADS split. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with the SEC to reflect the change in the ADS Ratio. The company anticipates that the change in the ADS Ratio will be effective on or about March 18, subject to the effectiveness of the post-effective amendment to the ADS registration statement on Form F-6 on or before that date.